Every 10-Q that Insulet Corporation (PODD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PODD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PODD filings page.
Insulet Corporation reported strong Q1 2026 results, with revenue of $761.7 million, up 33.9% from a year earlier, driven by 36.9% growth in Omnipod products and especially rapid international expansion.
Net income rose to $91.1 million and diluted EPS to $1.30, helped by higher volumes and pricing, partly offset by a lower gross margin of 69.5% due to increased inventory reserves and warranty costs from a voluntary Omnipod 5 medical device correction.
Operating cash flow was $113.8 million and free cash flow $89.5 million. Insulet ended the quarter with $480.4 million in cash and $948.1 million of net debt, and repurchased $300 million of stock under accelerated share repurchase agreements while extending and expanding its buyback authorization.
Insulet Corporation (PODD) reported strong Q3 2025 growth. Total revenue rose to $706.3 million from $543.9 million, driven by Omnipod sales in the U.S. at $497.1 million and International at $202.1 million. Gross profit reached $510.1 million with gross margin improving to 72.2%. Net income was $87.6 million, and diluted EPS was $1.24. Operating income increased to $117.7 million as the company continued to invest in R&D ($77.2 million) and SG&A ($315.2 million) to support Omnipod 5 expansion.
Year to date, operating cash flow was $386.0 million, cash and equivalents were $757.4 million, and net debt declined as Insulet retired its 0.375% Convertible Notes and issued $450 million 6.5% senior unsecured notes; total debt, net fell to $1,014.8 million from $1,379.8 million. The board authorized up to $125 million in share repurchases; $59.6 million was executed through Q3. In ongoing litigation, a final judgment included a permanent injunction and a monetary award reduced to $59.4 million; amounts were not recorded due to pending appeals and a partial stay for certain patients.